Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117
- 1 January 2009
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 366 (1-2) , 218-220
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administrationInternational Journal of Pharmaceutics, 2008
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 DiabetesDiabetes Care, 2005
- Carrier-based strategies for targeting protein and peptide drugs to the lungsThe AAPS Journal, 2005
- The Influence of GLP-1 on Glucose-Stimulated Insulin SecretionDiabetes, 2003
- Development of Glucagon-Like Peptide-1-Based Pharmaceuticals as Therapeutic Agents for the Treatment of DiabetesCurrent Pharmaceutical Design, 2001
- Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cellsDiabetologia, 1999
- Mouth and Oropharyngeal Deposition of Pharmaceutical AerosolsJournal of Aerosol Medicine, 1998
- Glucagon-like peptide-1(7–36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patternsJournal of Endocrinology, 1993
- Deposition of Inhaled Particles in Human LungsNature, 1966